Reports Q3 revenue $55M, consensus $48.08M. “We have continued to expand our customer base and partnerships this quarter,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re particularly excited about our new program with Pfizer to advance the discovery and development of novel RNA molecules. I’m also thrilled about the five-year strategic cloud and AI partnership we signed with Google Cloud to deploy and develop AI tools for biology and biosecurity. Our team is hard at work building new, state-of-the-art foundation models that speak the languages of biology, and I couldn’t be more excited about the opportunities that lie ahead.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
- Ginkgo Bioworks options imply 12.2% move in share price post-earnings
- Cathie Wood’s ARK Investment bought 468K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 473K shares of Ginkgo Bioworks today
- Xwell, Ginkgo Bioworks implement expanded CDC TGS program